Annual report
2934.TEDINET S100WL6P
Period2024-06-01 → 2025-05-31
Filed2025-08-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥294m | 2024-06-01 → 2025-05-31 | Cons. | Operating income |
| Operating income | −¥605m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Ordinary income | ¥232m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | −¥695m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥712m | 2021-06-01 → 2022-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥248m | 2024-06-01 → 2025-05-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.7bn | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥88m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥132m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss |
| Net income | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Total assets | ¥9.2bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥11.4bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2023-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.1bn | at 2022-05-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.2bn | at 2025-05-31 | Cons. | Liabilities |
| Total liabilities | ¥9.5bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31v | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥509m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥471m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥623m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥17.42 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-429.05 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.21 | 2024-06-01 → 2025-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥269.11 | at 2025-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥229.59 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥525.78 | at 2023-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 15.3% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 10.0% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.9% | 2024-06-01 → 2025-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 202 | at 2025-05-31 | Cons. | Number of employees |
| Employees | 315 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 255 | at 2023-05-31v | Cons. | Number of employees |
| Employees | 278 | at 2022-05-31v | Cons. | Number of employees |
| Revenue | ¥6.6bn | 2024-06-01 → 2025-05-31 | Standalone | Net sales |
| Revenue | ¥8.1bn | 2023-06-01 → 2024-05-31 | Standalone | Net sales |
| Revenue | ¥9.4bn | 2022-06-01 → 2023-05-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.5bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥263m | 2024-06-01 → 2025-05-31 | Standalone | Operating income |
| Operating income | −¥139m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Ordinary income | ¥199m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥219m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.7bn | 2022-06-01 → 2023-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥679m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥95m | 2024-06-01 → 2025-05-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.9bn | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Net income | ¥48m | 2024-06-01 → 2025-05-31 | Standalone | Profit loss |
| Net income | −¥2.1bn | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | −¥1.7bn | 2022-06-01 → 2023-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥450m | 2021-06-01 → 2022-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥425m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥6.5bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥7.9bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥5.8bn | at 2023-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.3bn | at 2022-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.6bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.6bn | at 2025-05-31 | Standalone | Liabilities |
| Total liabilities | ¥6.5bn | at 2024-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.9bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.4bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥2.8bn | at 2023-05-31v | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥657m | at 2024-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥831m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥94m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥9.54 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-438.4 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-357.08 | 2022-06-01 → 2023-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.75 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.43 | 2024-06-01 → 2025-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31v | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥371.65 | at 2025-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥280.35 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥589.16 | at 2023-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.99 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 29.8% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.6% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.4% | at 2023-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.9% | 2024-06-01 → 2025-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 40.3% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,220,195 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,137,046 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,892,098 | at 2023-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 64 | at 2025-05-31 | Standalone | Number of employees |
| Employees | 63 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 49 | at 2023-05-31v | Standalone | Number of employees |
| Employees | 54 | at 2022-05-31v | Standalone | Number of employees |
| Employees | 46 | at 2021-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 74
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-06-01 → 2025-05-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2024-06-01 → 2025-05-31 | ¥367,000 |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2025-05-31 | −¥141m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2025-05-31 | −¥141m |
| Reconciling Itemsreconciling | segment assets | at 2025-05-31 | ¥1.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2025-05-31 | −¥383m |
| Healthcare Marketing Businessreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥7m |
| Healthcare Marketing Businessreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥12m |
| Healthcare Marketing Businessreportable segment | employees | at 2025-05-31 | 65 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥9.8bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥9.7bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥120m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2025-05-31 | ¥1.4bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥127m |
| Healthcare Sales Businessreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥11m |
| Healthcare Sales Businessreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥5m |
| Healthcare Sales Businessreportable segment | employees | at 2025-05-31 | 84 pure |
| Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥6.1bn |
| Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥6.1bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥17m |
| Healthcare Sales Businessreportable segment | segment assets | at 2025-05-31 | ¥5.6bn |
| Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥42m |
| Medical Care Sales Businessreportable segment | capex | 2024-06-01 → 2025-05-31 | ¥36m |
| Medical Care Sales Businessreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥14m |
| Medical Care Sales Businessreportable segment | employees | at 2025-05-31 | 42 pure |
| Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥5.7bn |
| Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥5.7bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥4m |
| Medical Care Sales Businessreportable segment | segment assets | at 2025-05-31 | ¥467m |
| Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥508m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-06-01 → 2025-05-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-06-01 → 2025-05-31 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2025-05-31 | ¥21.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2025-05-31 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥141m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-05-31 | ¥7.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2025-05-31 | ¥677m |
| Reconciling Itemsreconciling | capex | 2023-06-01 → 2024-05-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2023-06-01 → 2024-05-31 | ¥2m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-05-31 | −¥243m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-05-31 | −¥243m |
| Reconciling Itemsreconciling | segment assets | at 2024-05-31 | ¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥588m |
| Healthcare Marketing Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥418m |
| Healthcare Marketing Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥10m |
| Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥6.6bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥6.3bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥232m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2024-05-31 | ¥2.2bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥129m |
| Healthcare Sales Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥2.3bn |
| Healthcare Sales Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥3m |
| Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥4.5bn |
| Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥4.5bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥993,000 |
| Healthcare Sales Businessreportable segment | segment assets | at 2024-05-31 | ¥6.0bn |
| Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥111m |
| Medical Care Sales Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥85m |
| Medical Care Sales Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥32m |
| Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥6.8bn |
| Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥6.8bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥9m |
| Medical Care Sales Businessreportable segment | segment assets | at 2024-05-31 | ¥1.9bn |
| Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥258m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-06-01 → 2024-05-31 | ¥2.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-06-01 → 2024-05-31 | ¥45m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2024-05-31 | ¥18.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2024-05-31 | ¥17.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥243m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-05-31 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2024-05-31 | −¥17m |
| Healthcare Marketing Businessreportable segment | employees | at 2025-05-31 | 13 pure |
| Healthcare Sales Businessreportable segment | employees | at 2025-05-31 | 26 pure |
| Medical Care Sales Businessreportable segment | employees | at 2025-05-31 | 14 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,716
| Item | Context | Value | Unit |
|---|---|---|---|
| Security code | FilingDateInstant | 29340 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ジェイフロンティア株式会社 | |
| Filer name in english | FilingDateInstant | J Frontier Co.,Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2024-06-01 | |
| Current period end date | FilingDateInstant | 2025-05-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2025-05-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-06-01 | |
| Comparative period end date | FilingDateInstant | 2024-05-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-05-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)㈱シーディ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)㈱アルファラン | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | Original text (Japanese)㈱イーエックス・パートナーズ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | Original text (Japanese)㈱ECスタジオ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | Original text (Japanese)(社)技美会 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | Original text (Japanese)㈱グリフィス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row7Member | Original text (Japanese)㈱ウェルヴィーナス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row8Member | ㈱ROSA BLU | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Policy on development of human resources and internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)管理職に占める女性労働者の割合 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)2025年５月末まで | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | ％ | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | Original text (Japanese)有給休暇取得率 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |